Tags

Type your tag names separated by a space and hit enter

Methylphenidate in the treatment of female adolescents with cooccurrence of attention deficit/hyperactivity disorder and borderline personality disorder: a preliminary open-label trial.
Int Clin Psychopharmacol. 2008 Jul; 23(4):228-31.IC

Abstract

Recent studies reported symptomatic overlap between attention deficit/hyperactivity disorder (ADHD) and borderline personality disorder (BPD). Methylphenidate (MPH) is the most efficient treatment for ADHD. We assessed the efficacy and tolerability of MPH treatment in adolescent females who met the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria for both disorders. Fourteen BPD/ADHD female adolescents aged 14-19 years were treated with MPH for 12 weeks, targeting ADHD, BPD symptoms, and aggressive behavior, as rated by ADHD-rating scale (ADHD-RS) and Clinical Global Impression-Severity (CGI-S) scale for BPD and aggressive behavior severity. A significant improvement was detected in both ADHD and BPD severity (baseline vs. end point, ADHD-RS: 33.1+/-4.8 vs. 17.6+/-5.2, P<0.001; BPD CGI-S: 4.6+/-0.8 vs. 3.4+/-0.8, P<0.0005, respectively) as well as in aggressive behavior (Aggression CGI-S: 3.5+/-1.3 vs. 1.8+/-0.5, P<0.001). MPH was well tolerated. MPH may be useful and well tolerated in treating some shared symptoms of ADHD and BPD among female adolescents. Controlled studies are needed to substantiate these findings.

Authors+Show Affiliations

Child and Adolescent Outpatient Clinic, Geha Mental Health Center, Petah Tiqva, Israel. pgolubchik@clalit.org.ilNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18446088

Citation

Golubchik, Pavel, et al. "Methylphenidate in the Treatment of Female Adolescents With Cooccurrence of Attention Deficit/hyperactivity Disorder and Borderline Personality Disorder: a Preliminary Open-label Trial." International Clinical Psychopharmacology, vol. 23, no. 4, 2008, pp. 228-31.
Golubchik P, Sever J, Zalsman G, et al. Methylphenidate in the treatment of female adolescents with cooccurrence of attention deficit/hyperactivity disorder and borderline personality disorder: a preliminary open-label trial. Int Clin Psychopharmacol. 2008;23(4):228-31.
Golubchik, P., Sever, J., Zalsman, G., & Weizman, A. (2008). Methylphenidate in the treatment of female adolescents with cooccurrence of attention deficit/hyperactivity disorder and borderline personality disorder: a preliminary open-label trial. International Clinical Psychopharmacology, 23(4), 228-31. https://doi.org/10.1097/YIC.0b013e3282f94ae2
Golubchik P, et al. Methylphenidate in the Treatment of Female Adolescents With Cooccurrence of Attention Deficit/hyperactivity Disorder and Borderline Personality Disorder: a Preliminary Open-label Trial. Int Clin Psychopharmacol. 2008;23(4):228-31. PubMed PMID: 18446088.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Methylphenidate in the treatment of female adolescents with cooccurrence of attention deficit/hyperactivity disorder and borderline personality disorder: a preliminary open-label trial. AU - Golubchik,Pavel, AU - Sever,Jonathan, AU - Zalsman,Gil, AU - Weizman,Abraham, PY - 2008/5/1/pubmed PY - 2008/10/18/medline PY - 2008/5/1/entrez SP - 228 EP - 31 JF - International clinical psychopharmacology JO - Int Clin Psychopharmacol VL - 23 IS - 4 N2 - Recent studies reported symptomatic overlap between attention deficit/hyperactivity disorder (ADHD) and borderline personality disorder (BPD). Methylphenidate (MPH) is the most efficient treatment for ADHD. We assessed the efficacy and tolerability of MPH treatment in adolescent females who met the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria for both disorders. Fourteen BPD/ADHD female adolescents aged 14-19 years were treated with MPH for 12 weeks, targeting ADHD, BPD symptoms, and aggressive behavior, as rated by ADHD-rating scale (ADHD-RS) and Clinical Global Impression-Severity (CGI-S) scale for BPD and aggressive behavior severity. A significant improvement was detected in both ADHD and BPD severity (baseline vs. end point, ADHD-RS: 33.1+/-4.8 vs. 17.6+/-5.2, P<0.001; BPD CGI-S: 4.6+/-0.8 vs. 3.4+/-0.8, P<0.0005, respectively) as well as in aggressive behavior (Aggression CGI-S: 3.5+/-1.3 vs. 1.8+/-0.5, P<0.001). MPH was well tolerated. MPH may be useful and well tolerated in treating some shared symptoms of ADHD and BPD among female adolescents. Controlled studies are needed to substantiate these findings. SN - 0268-1315 UR - https://www.unboundmedicine.com/medline/citation/18446088/Methylphenidate_in_the_treatment_of_female_adolescents_with_cooccurrence_of_attention_deficit/hyperactivity_disorder_and_borderline_personality_disorder:_a_preliminary_open_label_trial_ L2 - https://doi.org/10.1097/YIC.0b013e3282f94ae2 DB - PRIME DP - Unbound Medicine ER -